Notably, a closer examination of the cellular makeup within the prostate tumor cells revealed that in four out of the five post-treatment specimens, there was an increase in the cell proportions of PCA2 and PCA3 cells, along with a decrease in the proportion of PCA1 cells (Fig. 1h, i). The gene discussed is CASC19; the disease is prostate neoplasm.